VVN 461
Alternative Names: VVN-461Latest Information Update: 25 Jun 2024
At a glance
- Originator VivaVision Biotech
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Janus kinase 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Uveitis
Most Recent Events
- 15 May 2024 VivaVision Biotech completes a phase II trial in Uveitis in China (unspecified route) (NCT06164743)
- 19 Dec 2023 Phase-II clinical trials in Uveitis in China (unspecified route) (NCT06164743)
- 14 Dec 2023 VivaVision Biotech plans a phase II trial for Ocular inflammation in the US (Topical) (NCT06164743)